Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(12); doi: 10.25236/FMSR.2023.051206.

Progress and perspectives of cellular pyroptosis in digestive tract tumors


Jipeng Yang1,2,3, Jie Li1,2, Xiaoping Tan1,2, Qing Zhang1,2,3

Corresponding Author:
Xiaoping Tan

1Department of Gastroenterology, First Hospital of Yangtze University, Jingzhou, Hubei, China

2Digestive Disease Research Institution of Yangtze University, Jingzhou, Hubei, China

3Clinical Medical College, Yangtze University, Jingzhou, Hubei, China


Cellular pyroptosis, a novel mode of cell death in recent years, is triggered by cysteine asparaginase. Distinguished from traditional apoptosis and necrosis, this mode of cell death is characterized by the activation of inflammatory vesicles and the release of inflammatory factors. Its unique mechanism and morphological changes have attracted increasing attention regarding their role in the development and progression of gastrointestinal (GI) tumors. This has provided new insights and potential strategies for tumor prevention and treatment. Among these strategies, intervening in the process of cellular pyroptosis has been considered a promising approach to inhibit tumor growth. This review aims to explore the mechanism of cellular pyroptosis, its role in GI tumors, and its potential applications in therapy.


cellular pyroptosis, digestive tract tumors, mechanism

Cite This Paper

Jipeng Yang, Jie Li, Xiaoping Tan, Qing Zhang. Progress and perspectives of cellular pyroptosis in digestive tract tumors. Frontiers in Medical Science Research (2023) Vol. 5, Issue 12: 49-56. https://doi.org/10.25236/FMSR.2023.051206.


[1] Man S M, Karki R, Kanneganti T D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases[J]. Immunol Rev, 2017, 277(1): 61-75.

[2] Zhang K J, Wu Q, Jiang S M, et al. Pyroptosis: A New Frontier in Kidney Diseases[J]. Oxid Med Cell Longev, 2021, 2021: 6686617.

[3] Kong Q, Zhang Z. Cancer-associated pyroptosis: A new license to kill tumor[J]. Front Immunol, 2023, 14: 1082165.

[4] Hsu S K, Li C Y, Lin I L, et al. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment[J]. Theranostics, 2021, 11(18): 8813-8835.

[5] Zhou B, Zhao G, Li H, et al. FNDC5/PPARa Pathway Alleviates THP-1-derived Macrophage Pyroptosis and Its Mechanism[J]. Altern Ther Health Med, 2023, 29(3): 32-42.

[6] Yu P, Zhang X, Liu N, et al. Pyroptosis: mechanisms and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 128.

[7] Zheng Z, Li G. Mechanisms and Therapeutic Regulation of Pyroptosis in Inflammatory Diseases and Cancer [J]. Int J Mol Sci, 2020, 21(4).

[8] Lu L, Zhang Y, Tan X, et al. Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer[J]. Cell Death Discov, 2022, 8(1): 338.

[9] Campisi L, Cummings R J, Blander J M. Death-defining immune responses after apoptosis[J]. Am J Transplant, 2014, 14(7): 1488-1498.

[10] Ouyang X, Zhou J, Lin L, et al. Pyroptosis, inflammasome, and gasdermins in tumor immunity[J]. Innate Immun, 2023, 29(1-2): 3-13.

[11] Huang C, Li J, Zhang C. What role does pyroptosis play in cancer?[J]. Mol Metab, 2022, 65: 101587.

[12] Anderson M J, Den Hartigh A B, Fink S L. Molecular Mechanisms of Pyroptosis[J]. Methods Mol Biol, 2023, 2641: 1-16.

[13] Qi S, Wang Q, Zhang J, et al. Pyroptosis and Its Role in the Modulation of Cancer Progression and Antitumor Immunity[J]. Int J Mol Sci, 2022, 23(18).

[14] Dai Z, Liu W C, Chen X Y, et al. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors[J]. Front Immunol, 2023, 14: 1178662.

[15] Wei X, Xie F, Zhou X, et al. Role of pyroptosis in inflammation and cancer[J]. Cell Mol Immunol, 2022, 19(9): 971-992.

[16] Fang Y, Tian S, Pan Y, et al. Pyroptosis: A new frontier in cancer[J]. Biomed Pharmacother, 2020, 121: 109595.

[17] Tan Y, Chen Q, Li X, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 153.

[18] Wright S S, Vasudevan S O, Rathinam V A. Mechanisms and Consequences of Noncanonical Inflammasome-Mediated Pyroptosis[J]. J Mol Biol, 2022, 434(4): 167245.

[19] Wang W, Zhang L, Sun Z. Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies[J]. Cancer Biol Med, 2022, 19(7): 948-964.

[20] Wen R, Liu Y P, Tong X X, et al. Molecular mechanisms and functions of pyroptosis in sepsis and sepsis-associated organ dysfunction[J]. Front Cell Infect Microbiol, 2022, 12: 962139.

[21] Zhang D, Zhao F, Li J, et al. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma[J]. Aging (Albany NY), 2023, 15(15): 7811-7830.

[22] Shi Y, Yang Q, Tai G, et al. Expression of pyroptosis-related genes are correlated with immune microenvironment and predict prognosis in ESCA[J]. J Cancer Res Clin Oncol, 2023, 149(12): 10701-10713.

[23] Jiang M, Wu Y, Qi L, et al. Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma[J]. Chem Biol Interact, 2021, 350: 109704.

[24] Jiang M, Wu Y, Qi L, et al. Corrigendum to "Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma" [Chem. Biol. Interact. 350 (2021) 109704][J]. Chem Biol Interact, 2022, 352: 109765.

[25] Li R Y, Zheng Z Y, Li Z M, et al. Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer[J]. Chem Biol Interact, 2022, 361: 109967.

[26] Zheng Z Y, Yang P L, Li R Y, et al. STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma[J]. Cancer Lett, 2021, 522: 171-183.

[27] Chen J, Peng R, Niu Z, et al. Betulinic acid enhanced the chemical sensitivity of esophageal cancer cells to cisplatin by inducing cell pyroptosis and reducing cell stemness[J]. Ann Palliat Med, 2020, 9(4): 1912-1920.

[28] Wu M, Wang Y, Yang D, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma[J]. EBioMedicine, 2019, 41: 244-255.

[29] Aoude M, Mousallem M, Abdo M, et al. Gastric cancer in the Arab World: a systematic review[J]. East Mediterr Health J, 2022, 28(7): 521-531.

[30] Deng B B, Jiao B P, Liu Y J, et al. BIX-01294 enhanced chemotherapy effect in gastric cancer by inducing GSDME-mediated pyroptosis[J]. Cell Biol Int, 2020, 44(9): 1890-1899.

[31] Yin J, Che G, Wang W, et al. Investigating the Prognostic Significance of Pyroptosis-Related Genes in Gastric Cancer and Their Impact on Cells' Biological Functions[J]. Front Oncol, 2022, 12: 861284.

[32] Ren N, Jiang T, Wang C, et al. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis[J]. Aging (Albany NY), 2020, 12(11): 11025-11041.

[33] Xu J, Chen K, Wei Z, et al. Constructing and Validating a Pyroptosis-Related Genes Prognostic Signature for Stomach Adenocarcinoma and Immune Infiltration: Potential Biomarkers for Predicting the Overall Survival[J]. J Oncol, 2022, 2022: 3102743.

[34] Hu J, Song Y, Cai X, et al. A novel pyroptosis gene expression-based risk score for survival in gastric cancer[J]. Front Endocrinol (Lausanne), 2023, 14: 1120216.

[35] Zhang F, Yin Y, Xu W, et al. Icariin inhibits gastric cancer cell growth by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 signaling axis[J]. Hum Exp Toxicol, 2022, 41: 9603271221097363.

[36] Chu Q, Jiang Y, Zhang W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma[J]. Oncotarget, 2016, 7(51): 84658-84665.

[37] Li Y, Zhao R, Xiu Z, et al. Neobavaisoflavone induces pyroptosis of liver cancer cells via Tom20 sensing the activated ROS signal[J]. Phytomedicine, 2023, 116: 154869.

[38] Zhang Y, Yang H, Sun M, et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis[J]. Pharmacol Rep, 2020, 72(5): 1370-1382.

[39] Liang W F, Gong Y X, Li H F, et al. Curcumin Activates ROS Signaling to Promote Pyroptosis in Hepatocellular Carcinoma HepG2 Cells[J]. In Vivo, 2021, 35(1): 249-257.

[40] Wei Q, Zhu R, Zhu J, et al. E2-Induced Activation of the NLRP3 Inflammasome Triggers Pyroptosis and Inhibits Autophagy in HCC Cells[J]. Oncol Res, 2019, 27(7): 827-834.

[41] Song A, Ding T, Wei N, et al. Schisandrin B induces HepG2 cells pyroptosis by activating NK cells mediated anti-tumor immunity[J]. Toxicol Appl Pharmacol, 2023, 472: 116574.

[42] Huo S, Li B, Du J, et al. Dibutyl phthalate induces liver fibrosis via p38MAPK/NF-κB/NLRP3-mediated pyroptosis[J]. Sci Total Environ, 2023, 897: 165500.

[43] Wei R, Li S, Yu G, et al. Deciphering the Pyroptosis-Related Prognostic Signature and Immune Cell Infiltration Characteristics of Colon Cancer[J]. Front Genet, 2021, 12: 755384.

[44] Yu J, Li S, Qi J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells[J]. Cell Death Dis, 2019, 10(3): 193.

[45] Chen Y, Ma S, Pi D, et al. Luteolin induces pyroptosis in HT-29 cells by activating the Caspase1/Gasdermin D signalling pathway[J]. Front Pharmacol, 2022, 13: 952587.

[46] Yang F, Bettadapura S N, Smeltzer M S, et al. Pyroptosis and pyroptosis-inducing cancer drugs[J]. Acta Pharmacol Sin, 2022, 43(10): 2462-2473.

[47] Wang Q, Liu P, Wen Y, et al. Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases[J]. Mol Cancer, 2023, 22(1): 95.

[48] Guo J, Zheng J, Mu M, et al. GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis[J]. Biochem Biophys Res Commun, 2021, 548: 60-66.

[49] Cheng M Z, Yang B B, Zhan Z T, et al. MACC1 and Gasdermin-E (GSDME) regulate the resistance of colorectal cancer cells to irinotecan[J]. Biochem Biophys Res Commun, 2023, 671: 236-245.

[50] Feng W Q, Zhang Y C, Xu Z Q, et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration[J]. J Transl Med, 2023, 21(1): 335.

[51] Bai Z, Xu F, Feng X, et al. Pyroptosis regulators exert crucial functions in prognosis, progression and immune microenvironment of pancreatic adenocarcinoma: a bioinformatic and in vitro research[J]. Bioengineered, 2022, 13(1): 1717-1735.

[52] Chen Y, Liu Y, Wang M. Identification of a Pyroptosis-Related Gene Signature and Effect of Silencing the CHMP4C and CASP4 in Pancreatic Adenocarcinoma[J]. Int J Gen Med, 2022, 15: 3199-3213.

[53] Li S, Yue M, Xu H, et al. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer[J]. Cancer Lett, 2023, 564: 216206.

[54] Ding M, Liu J, Lv H, et al. Knocking down GALNT6 promotes pyroptosis of pancreatic ductal adenocarcinoma cells through NF-κB/NLRP3/GSDMD and GSDME signaling pathway[J]. Front Oncol, 2023, 13: 1097772.

[55] Liu Y, Zhang W, Zhou H, et al. Steroidal saponins PPI/CCRIS/PSV induce cell death in pancreatic cancer cell through GSDME-dependent pyroptosis[J]. Biochem Biophys Res Commun, 2023, 673: 51-58.

[56] Wang D, Wan X. Progress in the study of molecular mechanisms of cell pyroptosis in tumor therapy[J]. Int Immunopharmacol, 2023, 118: 110143.